GRI Bio, Inc.
GRI · NASDAQ
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.21 | 0.00 | 0.00 | 0.01 |
| FCF Yield | -51.90% | -112.17% | -181.53% | -101.56% |
| EV / EBITDA | -0.14 | 0.76 | 0.73 | 1.51 |
| Quality | ||||
| ROIC | -198.28% | -83.49% | -223.84% | -46.51% |
| Gross Margin | 46.88% | 0.00% | 48.42% | 0.00% |
| Cash Conversion Ratio | 0.69 | 1.09 | 0.57 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 3,067,654.55% | 2,824,596.50% | 2,824,596.50% | -100.00% |
| Free Cash Flow Growth | 26.94% | -82.37% | 13.16% | 11.86% |
| Safety | ||||
| Net Debt / EBITDA | 1.18 | 1.74 | 1.04 | 2.51 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -35.23 | -116,730.00 | -122,490.00 | -80,730.00 |